Nifty
Sensex
:
:
11095.25
37687.91
203.65 (1.87%)
748.31 (2.03%)

Pharmaceuticals & Drugs - Global

Rating :
63/99  (View)

BSE: 500124 | NSE: DRREDDY

4634.85
107.40 (2.37%)
04-Aug-2020 | 3:55PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  4530.70
  •  4654.35
  •  4490.15
  •  4527.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1666543
  •  77241.77
  •  4670.00
  •  2351.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 75,205.25
  • 38.68
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 77,210.15
  • 0.55%
  • 4.68

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.74%
  • 4.92%
  • 7.41%
  • FII
  • DII
  • Others
  • 29.33%
  • 14.41%
  • 17.19%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.86
  • 2.39
  • 7.05

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.70
  • -7.18
  • 0.99

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.03
  • -1.34
  • 29.25

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.35
  • 30.78
  • 29.89

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.41
  • 3.76
  • 3.26

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.06
  • 17.11
  • 16.07

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
4,426
3,858
15%
4,449
4,030
10%
4,397
3,865
14%
4,813
3,818
26%
Expenses
3,305
3,116
6%
3,500
3,211
9%
4,686
3,060
53%
3,749
3,058
23%
EBITDA
1,121
742
51%
949
819
16%
-289
805
-
1,064
759
40%
EBIDTM
25%
19%
21%
20%
-7%
21%
22%
20%
Other Income
87
430
-80%
74
83
-12%
67
102
-34%
54
128
-58%
Interest
23
30
-22%
23
24
-6%
15
24
-37%
30
21
46%
Depreciation
292
289
1%
274
287
-5%
287
290
-1%
313
279
12%
PBT
893
853
5%
726
590
23%
-524
592
-
774
588
32%
Tax
306
193
59%
-45
151
-
32
101
-68%
-321
81
-
PAT
587
660
-11%
771
440
75%
-556
491
-
1,095
507
116%
PATM
13%
17%
17%
11%
-13%
13%
23%
13%
EPS
41.07
46.20
-11%
53.93
30.77
75%
-38.91
34.39
-
76.63
35.51
116%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
18,085
17,517
15,448
14,281
14,196
15,568
15,023
13,415
11,896
9,814
7,497
Net Sales Growth
16%
13%
8%
1%
-9%
4%
12%
13%
21%
31%
 
Cost Of Goods Sold
5,667
5,554
4,495
4,040
3,696
3,758
3,786
3,317
3,517
2,568
2,091
Gross Profit
12,418
11,963
10,953
10,242
10,500
11,810
11,237
10,098
8,379
7,246
5,406
GP Margin
69%
68%
71%
72%
74%
76%
75%
75%
70%
74%
72%
Total Expenditure
15,240
15,047
12,270
11,930
11,724
11,983
11,530
10,165
9,176
7,375
5,936
Power & Fuel Cost
-
315
329
329
330
315
339
320
335
226
183
% Of Sales
-
2%
2%
2%
2%
2%
2%
2%
3%
2%
2%
Employee Cost
-
3,380
3,356
3,215
3,107
3,117
2,945
2,475
1,929
1,591
1,305
% Of Sales
-
19%
22%
23%
22%
20%
20%
18%
16%
16%
17%
Manufacturing Exp.
-
1,445
1,435
1,746
1,887
1,856
1,999
1,748
1,441
1,237
986
% Of Sales
-
8%
9%
12%
13%
12%
13%
13%
12%
13%
13%
General & Admin Exp.
-
1,195
1,144
1,193
1,340
1,271
1,037
1,004
796
683
479
% Of Sales
-
7%
7%
8%
9%
8%
7%
7%
7%
7%
6%
Selling & Distn. Exp.
-
1,408
1,424
1,330
1,293
1,181
1,358
1,265
1,119
984
745
% Of Sales
-
8%
9%
9%
9%
8%
9%
9%
9%
10%
10%
Miscellaneous Exp.
-
1,748
88
76
71
483
66
36
38
85
745
% Of Sales
-
10%
1%
1%
0%
3%
0%
0%
0%
1%
2%
EBITDA
2,846
2,470
3,178
2,351
2,472
3,585
3,494
3,251
2,720
2,440
1,561
EBITDA Margin
16%
14%
21%
16%
17%
23%
23%
24%
23%
25%
21%
Other Income
282
621
338
155
172
295
274
170
150
132
52
Interest
92
98
89
79
63
83
108
127
100
114
32
Depreciation
1,166
1,163
1,135
1,077
1,027
939
760
648
550
518
398
PBT
1,869
1,830
2,292
1,350
1,554
2,859
2,900
2,646
2,219
1,940
1,183
Tax
-27
-140
386
438
296
751
563
683
638
504
184
Tax Rate
-1%
-8%
17%
32%
19%
26%
19%
26%
29%
28%
16%
PAT
1,897
1,970
1,906
912
1,257
2,108
2,336
1,963
1,527
1,301
999
PAT before Minority Interest
1,897
1,970
1,906
912
1,257
2,108
2,336
1,963
1,527
1,301
999
Minority Interest
0
0
0
0
0
0
0
0
0
0
0
PAT Margin
10%
11%
12%
6%
9%
14%
16%
15%
13%
13%
13%
PAT Growth
-10%
3%
109%
-27%
-40%
-10%
19%
29%
17%
30%
 
EPS
132.72
137.85
133.39
63.85
87.98
147.49
163.50
137.38
106.84
91.04
69.90

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
15,599
14,024
12,572
12,262
12,570
9,853
7,865
6,369
4,989
4,032
Share Capital
83
83
83
83
85
85
85
85
85
85
Total Reserves
15,412
13,861
12,406
12,099
12,394
9,677
7,699
6,215
4,849
3,907
Non-Current Liabilities
-808
2,113
2,538
456
877
1,678
2,182
1,285
1,610
600
Secured Loans
130
55
63
60
75
78
95
80
26
24
Unsecured Loans
0
2,145
2,446
485
994
1,354
1,981
1,186
1,616
513
Long Term Provisions
74
79
82
84
95
78
56
51
33
29
Current Liabilities
7,214
5,897
6,894
8,420
6,347
6,821
5,790
5,659
4,591
4,208
Trade Payables
1,525
1,367
1,334
1,057
907
867
893
966
757
634
Other Current Liabilities
3,512
2,821
2,411
2,340
2,409
2,624
2,021
2,120
1,749
1,329
Short Term Borrowings
1,653
1,212
2,556
4,363
2,272
2,186
2,061
1,899
1,589
1,832
Short Term Provisions
524
497
592
661
759
1,144
816
674
497
413
Total Liabilities
22,005
22,034
22,004
21,138
19,794
18,353
15,838
13,313
11,190
8,841
Net Block
6,850
7,191
6,968
6,931
6,563
5,377
4,641
4,051
3,412
3,386
Gross Block
19,336
18,048
17,436
15,932
15,020
12,574
11,918
10,089
8,842
7,975
Accumulated Depreciation
12,146
10,846
10,468
9,002
8,457
7,170
7,277
5,985
5,295
4,590
Non Current Assets
9,406
10,924
11,505
11,454
8,000
6,476
5,512
4,786
4,191
4,026
Capital Work in Progress
1,535
2,934
3,470
3,324
772
529
639
565
708
575
Non Current Investment
309
334
465
683
330
146
0
0
1
1
Long Term Loans & Adv.
689
427
565
482
290
418
232
149
70
64
Other Non Current Assets
23
38
37
34
44
6
0
21
0
0
Current Assets
12,599
11,110
10,498
9,684
11,794
11,877
10,326
8,527
6,999
4,815
Current Investments
2,369
2,253
1,833
1,427
3,503
2,102
1,066
197
207
0
Inventories
3,507
3,358
2,909
2,853
2,558
2,570
2,419
2,171
1,943
1,599
Sundry Debtors
5,028
3,987
4,053
3,799
4,125
4,101
3,325
3,180
2,537
1,761
Cash & Bank
205
223
264
386
492
1,872
2,301
2,017
1,606
575
Other Current Assets
1,491
850
766
452
1,116
1,231
1,215
962
706
880
Short Term Loans & Adv.
444
440
674
767
722
1,005
1,044
797
612
763
Net Current Assets
5,385
5,213
3,605
1,264
5,447
5,055
4,535
2,868
2,408
606
Total Assets
22,005
22,034
22,004
21,138
19,794
18,353
15,838
13,313
11,190
8,841

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
2,984
2,870
1,803
2,144
3,263
2,524
1,970
1,378
1,613
755
PBT
1,886
2,292
1,350
1,554
2,859
2,900
2,646
2,165
1,804
1,183
Adjustment
2,562
1,640
1,625
1,687
1,108
1,654
1,043
1,063
1,157
530
Changes in Working Capital
-754
-577
-897
-520
-2
-1,484
-1,005
-1,294
-894
-659
Cash after chg. in Working capital
3,695
3,354
2,079
2,721
3,964
3,070
2,684
1,933
2,068
1,054
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-710
-484
-276
-577
-701
-546
-714
-555
-455
-299
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-492
-773
-1,488
-1,840
-2,039
-2,265
-1,694
-1,446
-1,888
-899
Net Fixed Assets
-454
-276
-683
-1,019
-1,892
-828
-820
-531
-554
-400
Net Investments
-1,552
-297
-535
1,974
-1,214
-1,056
-427
98
-16
93
Others
1,513
-200
-270
-2,795
1,067
-381
-447
-1,014
-1,318
-592
Cash from Financing Activity
-2,516
-2,133
-444
-369
-1,700
-433
-24
-157
389
44
Net Cash Inflow / Outflow
-24
-35
-129
-65
-477
-174
251
-225
113
-99
Opening Cash & Equivalents
223
254
378
492
540
862
520
736
573
660
Closing Cash & Equivalent
196
223
254
378
492
583
862
520
736
575

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
932
840
752
735
731
573
457
371
291
236
ROA
9%
9%
4%
6%
11%
14%
13%
12%
13%
12%
ROE
13%
14%
7%
10%
19%
27%
28%
27%
29%
26%
ROCE
11%
13%
8%
10%
20%
23%
25%
25%
26%
21%
Fixed Asset Turnover
0.94
0.87
0.86
0.92
1.13
1.23
1.23
1.26
1.17
1.04
Receivable days
94
95
100
102
96
90
88
87
80
71
Inventory Days
72
74
74
70
60
60
62
63
66
71
Payable days
40
39
37
31
29
28
34
35
35
72
Cash Conversion Cycle
126
130
137
140
128
122
116
115
110
70
Total Debt/Equity
0.14
0.28
0.41
0.40
0.27
0.44
0.58
0.58
0.66
0.59
Interest Cover
20
27
18
26
36
28
22
23
17
38

News Update


  • Dr. Reddy's Laboratories reports 12% fall in Q1 consolidated net profit
    30th Jul 2020, 10:35 AM

    Total income of the company increased by 5.25% at Rs 4513.60 crore for Q1FY21

    Read More
  • Dr. Reddy's Laboratories receives approval of XEGLYZE lotion in US
    27th Jul 2020, 13:06 PM

    The company is working to commercialize this product through partners

    Read More
  • Dr. Reddy's Laboratories launches over-the-counter Nicotine Polacrilex Lozenges
    14th Jul 2020, 13:40 PM

    The company’s Nicotine Polacrilex Lozenges are available in multiple pack sizes based on consumers’ requirements

    Read More
  • Dr. Reddy's expecting overall performance to be quite volatile in current fiscal
    6th Jul 2020, 14:02 PM

    As per the company, overall, there was no major impact of the pandemic during the last fiscal, including the fourth quarter

    Read More
  • Dr Reddy's Laboratories inks pact with FUJIFILM, Global Response Aid
    1st Jul 2020, 13:55 PM

    The company has partnered for the development, manufacture and sales of Avigan Tablets a potential treatment of COVID-19

    Read More
  • Dr Reddy's expects to launch 25 products in US market in FY21
    29th Jun 2020, 09:11 AM

    The drug major has also earmarked a capex of Rs 1,000 crore for finding various projects during the ongoing financial year

    Read More
  • Dr. Reddy's Laboratories working on four new products
    23rd Jun 2020, 16:08 PM

    The new compounds are in the therapeutic areas of paediatrics, dermatology, haematology-oncology

    Read More
  • Dr. Reddy's launches Abiraterone Acetate Tablets in US market
    19th Jun 2020, 14:55 PM

    The company’s Abiraterone Acetate is available in 250 mg tablets in bottle count sizes of 120

    Read More
  • Dr. Reddy's enters into licensing agreement with Gilead Sciences
    13th Jun 2020, 14:27 PM

    The company will receive technology transfer from Gilead for manufacturing drug, Remdesivir

    Read More
  • Dr. Reddy's launches Colchicine tablets in US market
    13th Jun 2020, 09:56 AM

    The company's Colchicine is available in 0.6 mg tablets in bottle count sizes of 30s and 100s

    Read More
  • Dr. Reddy's completes acquisition of select business divisions of Wockhardt
    11th Jun 2020, 09:05 AM

    The company has completed the acquisition of select divisions of Wockhardt’s branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives

    Read More
  • Dr. Reddy's Lab gets EIR for API Srikakulam Plant in Andhra Pradesh
    1st Jun 2020, 09:38 AM

    The company has received the EIR from the USFDA, indicating that the inspection is closed under 21 CFR 20.64(d)(3)

    Read More
  • Dr. Reddy's Lab gets EIR for Integrated Product Development Organization at Telangana
    28th May 2020, 13:16 PM

    The company has received the Establishment Inspection Report from USFDA

    Read More
  • Dr. Reddy's Lab gets EIR for formulations manufacturing plant in Hyderabad
    20th May 2020, 10:32 AM

    The company has received the EIR from USFDA

    Read More
  • Dr. Reddys Lab - Quarterly Results
    20th May 2020, 12:00 AM

    Read More
  • Dr. Reddy's Lab gets EIR for formulations Srikakulum plant in Andhra Pradesh
    14th May 2020, 10:11 AM

    The inspection classification of this facility is determined as No Action Indicated

    Read More
  • Dr. Reddy's recalling 1,752 bottles of generic heartburn medicine in US
    11th May 2020, 10:19 AM

    The ongoing Class III recall is on account of Discolouration and because the product contains brown pellets

    Read More
  • Dr. Reddy's Lab gets EIR for Andhra Pradesh plant
    8th May 2020, 14:27 PM

    The inspection classification of this facility is determined as Voluntary Action Indicated

    Read More
  • Dr. Reddy's gets USFDA’s nod for migraine treatment oral solution
    7th May 2020, 09:06 AM

    ELYXYB is indicated for the acute treatment of migraine with or without aura in adults

    Read More
  • Dr. Reddy's launches Desmopressin Acetate Injection USP
    6th May 2020, 14:08 PM

    Desmopressin Acetate Injection USP, 4 mcg/mL is available in a carton of ten 1 mL single dose ampules

    Read More
  • Dr Reddy's Laboratories launches Fenofibrate Tablets USP in US Market
    27th Apr 2020, 13:15 PM

    The company’s Fenofibrate Tablets USP, are available in 54 mg dose in bottle count size of 90

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.